Bottom line
PJP vs XPH: the short answer
PJP (Invesco Pharmaceuticals ETF) and XPH (State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF) are quite different portfolios: only about 18% of their top holdings (by weight) are shared.
But XPH is far broader, holding 67 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
XPH is cheaper at 0.35% vs 0.58% — a difference of $23 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +2.8% for XPH.
Updated Nov 19, 2026
PJP vs XPH side by side
| PJP | XPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.35% |
| Annual cost per $10k | $58 | $35 |
| 10-yr cost on $10k (prospectus) | $726 | $443 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +27.9% | +31.6% |
| 5-yr return (annualized) | +9.0% | +2.8% |
| 10-yr return (annualized) | +5.1% | +1.9% |
| Best quarter | +18.1% | +28.6% |
| Worst quarter | −14.8% | −24.3% |
| Net assets (fund) | $472.1M | $428.4M |
| Number of holdings | 33 | 67 |
| Portfolio turnover | 36% | 69% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | XPH | Difference |
|---|---|---|---|
| 2025 | +27.9% | +31.6% | −3.7% |
| 2024 | +9.7% | +5.1% | +4.6% |
| 2023 | −2.2% | +2.9% | −5.1% |
| 2022 | −2.0% | −9.8% | +7.7% |
| 2021 | +14.5% | −10.5% | +25.0% |
| 2020 | +11.2% | +14.4% | −3.2% |
| 2019 | +4.7% | +25.7% | −21.0% |
| 2018 | −1.7% | −15.2% | +13.5% |
| 2017 | +15.3% | +12.0% | +3.3% |
| 2016 | −19.3% | −23.2% | +4.0% |
Source: Fund prospectus bar charts
Holdings overlap
6 of PJP's top 25 holdings also appear in XPH's top 25.
| Holding | PJP | XPH |
|---|---|---|
| Merck & Co., Inc. | 5.06% | 1.65% |
| Corcept Therapeutics Inc. | 4.96% | 1.70% |
| Amneal Pharmaceuticals, Inc. | 3.75% | 1.72% |
| Liquidia Corp. | 3.66% | 1.86% |
| Ligand Pharmaceuticals Inc. | 3.20% | 1.94% |
| Ocular Therapeutix, Inc. | 2.58% | 1.71% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
XPH top 10
- State Street Global Advisors — 8.58%
- Definium Therapeutics Inc — 3.09%
- MBX Biosciences Inc — 2.72%
- Alumis Inc — 2.14%
- AtaiBeckley Inc — 2.13%
- Trevi Therapeutics Inc — 2.12%
- Enliven Therapeutics Inc — 2.09%
- Amylyx Pharmaceuticals Inc — 2.04%
- VeraDermics Inc — 2.02%
- Ligand Pharmaceuticals Inc — 1.94%
FAQ
What is the difference between PJP and XPH?
Which is cheaper, PJP or XPH?
Should I own both PJP and XPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.